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A B S T R A C T
Pro-tumorigenic activities of matrix metalloproteinase (MMP) 9 have been linked to many cancers, but recently
the tumour-suppressing role of MMP9 has also been elucidated. The multifaceted evidence on this subject
prompted us to examine the role of MMP9 in the behaviour of oral tongue squamous cell carcinoma (OTSCC)
cells. We used gelatinase-speciﬁc inhibitor, CTT2, and short hairpin (sh) RNA gene silencing to study the eﬀects
of MMP9 on proliferation, motility and invasion of an aggressive OTSCC cell line, HSC-3. We found that the
migration and invasion of HSC-3 cells were increased by CTT2 and shRNA silencing of MMP9. Proliferation, in
turn, was decreased by MMP9 inhibition. Furthermore, arresten-overexpressing HSC-3 cells expressed increased
levels of MMP9, but exhibited decreased motility compared with controls. Interestingly, these cells restored their
migratory capabilities by CTT2 inhibition of MMP9. Hence, although higher MMP9 expression could give rise to
an increased tumour growth in vivo due to increased proliferation, in some circumstances, it may participate in
yet unidentiﬁed molecular mechanisms that reduce the cell movement in OTSCC.
1. Introduction
Oral tongue squamous cell carcinoma (OTSCC) is globally the most
frequent type of oral cancer in terms of epidemiology [1]. It is a highly
aggressive cancer associated with a low rate of local tumour control,
and, despite advances in diagnostics and therapeutics, the 5-year sur-
vival rate remains low, around 60% [2].
Matrix metalloproteinases (MMPs) are, in general, considered key
players in cancer progression due to their capability to degrade tissue
barriers, allowing tumour cells to invade and metastasize. However,
MMPs have far more complex roles in cancer, and some MMPs are now
also shown to suppress some aspects of cancer progression [3].
MMP9 has conventionally been considered as a pro-tumorigenic
enzyme in oral squamous cell carcinoma (OSCC). A recent meta-ana-
lysis study showed that MMP9 overexpression is a predictor of poor
prognosis in OTSCC patients [4]. However, whether MMP9 expression
in the most aggressive tumours enhances tumour progression or is more
a consequence of tumour aggressiveness is unknown. Previous studies
have revealed both pro- and anti-tumorigenic roles of MMP9 (reviewed
in detail by Vilen et al. [5]), and its role in oral cancer is far from clear
[5]. Jordan et al. [6] found that the mRNA levels of MMP9 were sig-
niﬁcantly higher in oral dysplasias that progressed to oral cancer than
in those that did not [6]. Pro- and active forms, total activities and the
activation ratio of MMP9 were also signiﬁcantly elevated in OSCC
samples compared with their adjacent areas histologically rated as
normal tissues [7]. In contrast, Stokes et al. [8] showed that MMP9
mRNA in primary tumours compared with adjacent peritumoral tissues
was signiﬁcantly decreased in head and neck squamous cell carcinomas
with lymph node metastasis compared with non-metastatic tumours
[8]. Moreover, Lin et al. [9] demonstrated that although patients with
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OSCC exhibit signiﬁcantly higher levels of MMP9 than healthy controls,
and even though MMP9 plasma levels are associated with more ad-
vanced clinical stages, MMP9 level was not associated with positive
lymph node or distal metastasis [9]. Evidence for the oncosuppressive
role of MMP9 has also emerged for other cancers such as colitis-asso-
ciated cancers [10] and breast cancer when MMP9 is produced by
cancer cells [11].
Recently, we have reported increased MMP9 expression in HSC-3
clone overexpressing MMP8 with decreased migration and invasion
[12]. Additionally, although anti-MMP2 and -9 peptides inhibit tongue
carcinoma growth [13,14] and angiogenesis [13], they do not prevent
the spread of carcinoma cells in nude mice [14]. Instead, when anti-
MMP2 and -9 peptides were used in combination with proMMP9 tar-
geting therapy, increased HSC-3 tumour growth was observed in mice
[14].
This study aims to elucidate the role of MMP9 in the behaviour of
aggressive oral tongue carcinoma cells in vitro by using various ge-
netically modiﬁed cell models with altered MMP9 expression as well as
inhibition of MMP9 by gelatinase (MMP2 and -9) inhibitor peptide
CTT2 [15].
2. Materials and methods
2.1. Cell culture
2.1.1. Native cell lines
Human tongue squamous cell carcinoma cell lines HSC-3 (Japanese
Collection of Research Bioresources (JCRB) Cell Bank, JCRB0623), SAS
(JCRB Cell Bank, JCRB0260), SCC-25 (American Type Culture
Collection (ATCC), CRL 1628), human malignant melanoma G361
(ATCC, CRL-1424) and human Caucasian breast adenocarcinoma cell
line MDA-MB-231 (ATCC, HTB-26) were cultured in Dulbecco's mod-
iﬁed Eagle's medium (DMEM)/F-12, 1:1 (Gibco) supplemented with
10% heat-inactivated foetal bovine serum (FBS, Gibco), 50 μg/ml as-
corbic acid, 100 U/ml penicillin, 100 μg/ml streptomycin, 250 ng/ml
amphotericin B and 0.4 µg/ml hydrocortisone (all from Sigma-Aldrich).
Human embryonic kidney cell HEK-293 (ATCC, CRL-1573), human
gingival ﬁbroblasts (GFs) and human spontaneously immortalized
keratinocytes (HaCaT) [16] were cultured in DMEM (Sigma-Aldrich)
supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin,
100 μg/ml streptomycin, 50 μg/ml ascorbic acid, 250 ng/ml ampho-
tericin B and 1mM sodium pyruvate (all from Sigma-Aldrich). GFs used
in this study were obtained from biopsies of healthy gingiva as de-
scribed earlier [17]. The human papillomavirus HPV16 immortalized
human oral epithelial cells (IHGK) [18] were cultured in Keratinocyte-
SFM (Gibco) supplemented with 5 ng/ml human recombinant epi-
dermal growth factor, 50 µg/ml bovine pituitary extract (both from
Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin, 250 ng/ml am-
photericin B and 100 µM CaCl2 (all from Sigma Aldrich). Information
on the native cell lines used in this study is presented in Supplementary
Table S1.
2.1.2. Transduced and transfected cell lines
HSC-3 and SAS cells were stable transduced with three diﬀerent
commercial human GIPZ MMP9 lentiviral shRNAmir particles (Thermo
Fischer Open Biosystems) according to the manufacturer's instructions
with puromycin (Sigma-Aldrich) selection. HSC-3 cells transduced with
the non-silencing scrambled GIPZ lentiviral shRNAmir particles
(Thermo Fischer Open Biosystems) were used as a control cell line
(control HSC-3 cells) MMP9 silencing was conﬁrmed by semi-quanti-
tative PCR and zymography, and the expression level of MMP9 in
conditioned media of shMMP9 and control cells was regularly tested
before experiments by zymography (described below). HSC-3 cells with
stable overexpression of human arresten (arrHSC-3) is described in
Aikio et al. [19]. HEK-293 cells grown under the selective pressure of
Geneticin G418 antibiotic were used to purify recombinant human
arresten in an anti-ﬂag aﬃnity column as described previously [19]. All
cells were cultured in a humidiﬁed atmosphere of 5% CO2 at 37 °C and
passaged routinely using trypsin-EDTA (Sigma-Aldrich). Mycoplasma
infection was excluded by regular testing with MycoTrace PCR Detec-
tion Kit (PAA Laboratories GmbH).
2.2. RNA extraction and PCR
Total RNA was extracted from subconﬂuent shMMP9 and control
HSC-3 cells with TRI Reagent (Sigma-Aldrich) according to the manu-
facturer's instructions. cDNA was synthesized with SuperScript® III
First-Strand Synthesis System (Life Technologies) and semi-quantitative
PCR reactions were conducted with AmpliTaq Gold® DNA Polymerase
(Life Technologies) using MMP9 forward primer 5′-CACTGTCCACCCC
TCAGAGC-3′ and reverse primer 5′-GCCACTTGTCGGCGATAAGG-3′ as
described earlier [20]. As a control of the RNA amount, β-actin was
measured from the same cDNA samples using forward primer 5′-AAC
TGGGACGACATGGAGAAAA-3′ and reverse primer 5′-AGAGGCGTACA
GGGATAGCACA-3′. The annealing temperature was 64 °C for MMP9
and 54 °C for β-actin.
2.3. Zymography
Subconﬂuent cultures of HaCaT, HGF, IHGK, SCC-25 and HSC-3
(control and shMMP9) and MDA-MB-231 cells were cultured in Opti-
MEM (Gibco) and control and arrHSC-3 in 1% lactalbumin (Sigma-
Aldrich) medium for 24 h and media were collected for zymography. In
some cases, the cell layers were scratched by pipette tip and media were
collected after 24 h and 48 h with their unscratched controls.
Zymography was performed as previously described [21] using either
the same media protein amount or sample volume. The cells were lysed
for zymography as described in the ‘Western blot’ section.
2.4. Myoma organotypic cultures and immunohistochemistry
Myoma organotypic cultures were prepared as previously described
[22,23]. Brieﬂy, uterine leiomyoma tissue was obtained during routine
surgeries with the informed consent of the donors. The study protocol
was approved by the Regional Ethics Committee of the Northern Os-
trobothnia Hospital District (statement number 35/2014). The myoma
discs were cut with an 8mm biopsy punch. In some experiments,
myomas were rinsed in cell culture medium at 4 °C for 10 days prior to
cell culturing to remove soluble factors [24]. The rinsing medium was
changed twice a week. Myoma discs were placed into Transwell® inserts
(diameter 6.5mm; Corning) and 3× 105 or 7× 105 HSC-3 cells in 50 µl
of medium were added on the top of the myoma disc. The next day, the
discs were transferred onto uncoated nylon membrane (Prinsal Oy)
resting on curved steel grids in 12-well plates with 1ml of medium.
Cells were cultured on the top of the myoma disc for 10–14 days. In
some experiments, 100 µM CTT2-peptide GRENYHGCTTHWGFTLC
[15] and its scrambled control peptide LEHGTFCGRYTGCWNHT (both
from Polypeptide group) or 100 nM or 500 nM recombinant arresten
was added before the discs were placed into Transwell® inserts.
The tissues were ﬁxed in 4% neutral-buﬀered formalin overnight,
dehydrated and embedded in paraﬃn. Then 6-μm sections were de-
paraﬃnized and endogenous peroxidase was blocked with H2O2 in
methanol as the specimens were prepared for immunohistochemistry
with monoclonal pan-cytokeratin AE1/AE3 antibody (Dako) to identify
carcinoma cells, and invasion was quantiﬁed as described earlier
[22,23]. Brieﬂy, histological sections were photographed with a DMRB
photo microscope connected to a DFC-480 camera using QWin V3
software (Leica Microsystems) or with an Olympus BX61 light-ﬁeld
microscope equipped with an Olympus U-CMAB3 camera. The invasion
depth and areas of non-invading and invading cells were measured with
QWin V3 software, and the invasion index was calculated as previously
described [22,23].
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2.5. Transwell® migration assay
Transwell® membrane inserts with 8 µm pores (Corning) were
equilibrated with 600 µl of cell culture medium for 1 h before adding
the cells. Then 7× 104 shMMP9, arresten-overexpressing, corre-
sponding control or parental HSC-3, SAS, SCC-25 or MDA-MB-231 cells
were seeded into the upper chamber of Transwell® inserts in medium
containing 0.5% lactalbumin. CTT2 was added to the upper chamber in
serum-free medium after the cells had attached for 3 h. The medium in
the lower chamber contained 10% FBS. After 24 h or 48 h, the cells
were ﬁxed with 10% trichloroacetic acid (TCA) for 15min, washed
three times with dH2O, allowed to dry and stained with 0.1% crystal
violet. Cells from the upper side of the membrane were removed by
using a cotton swab. Membranes were detached from the inserts by
using a scalpel, attached to glass slides and photographed with a mi-
croscope using Leica Application Suite (LAS) software (Leica
Microsystems). The area of cells and total membrane area were mea-
sured using QWin V3 software (Leica Microsystems), and the percen-
tage of cell area was calculated. Alternatively, the cells were ﬁxed and
stained with Toluidine Blue. After removing the cells and excess dye
from the upper side of the membrane, the dye of migrated cells was
eluted with 1% SDS and the absorbance was measured at 650 nm using
a Victor2 Microplate Reader (Perkin Elmer Wallac) [25].
2.6. Scratch wound healing assays
In these assays, 2.5× 105 shMMP9 or control HSC-3 cells were al-
lowed to attach overnight in 24-well plates. The cell cultures were
scratched with 1ml pipette tip, and the wells were rinsed with serum-
free medium before adding medium with 1% FBS. The cells were
photographed with an EVOS photo microscope. In some cases, 24-well
plates were coated with 70 µg/ml rat tail type I collagen (BD
Biosciences), 10 µg/ml ﬁbronectin (Sigma-Aldrich) and 0.62mg/ml
Matrigel® (BD Biosciences) for 2 h in 37 °C and washed twice with PBS.
Next, 9× 104 shMMP9 or control HSC-3 cells were allowed to attach
overnight before wounding with the pipette tip, rinsed twice with PBS,
re-coated for 1 h and washed. The open area between the two cell edges
was measured with QWin V3 or Fiji software [26]. The results were
calculated as a percentage of the original empty area (0 h).
2.7. Cell proliferation assay
Cell proliferation was measured with Cell Proliferation ELISA, BrdU
(colorimetric) kit (Roche Diagnostics) according to the manufacturer's
instructions. Next, 1× 104 control, shMMP9 or arrHSC-3 HSC-3 cells
were allowed to attach in 96–well plates overnight, 24 or 48 h before
adding 10 µl BrdU–labelling reagent. The incorporation of 5-bromo-2′-
deoxyuridine (BrdU) into newly synthesized DNA of proliferating cells
was measured by absorbance at 450 nm using a Victor2 Microplate
Reader (Perkin Elmer Wallac).
2.8. Microarray
shMMP9 and control HSC-3 cells were cultured in triplicate in 6-
well plates. The next day, the cells were scratched with a 1ml pipette
tip at ~2.5mm intervals horizontally and vertically (migratory phe-
notype); three wells were left unwounded (stationary phenotype).
Medium with 1% FBS was added after 10 h and the total RNA was
extracted using RNEasy Mini Kit (Qiagen) according to the manufac-
turer's instructions. Microarray was performed and analysed by
Aﬀymetrix GeneChip Human Genome U133 Plus 2.0 according to the
Aﬀymetrix GeneChip Expression Analysis Technical Manual's instruc-
tions using 1 μg of total RNA as template (described in detail previously
[12]). The arrays were scanned on a GeneChip Scanner 3000 and
DAVID 6.7 was used for Gene Ontology analyses [27].
2.9. Western blot
Equal number of cells were lysed in 50mM Tris-HCl pH 7.5, 10mM
CaCl2, 150mM NaCl, 0.05% (v/v) Brij-35 (Sigma-Aldrich) buﬀer in-
cluding Complete mini EDTA-free protease inhibitor cocktail (Roche).
The cell debris was removed by centrifugation. The protein con-
centrations were measured with DC Protein assay (Bio-Rad) and 20 µg
of soluble proteins were separated under reducing conditions by 12%
SDS-PAGE gels and transferred to an Immobilon-P membrane
(Millipore). The membranes were blocked with 5% milk powder or 5%
BSA (for Phospho-antibodies) in Tris-buﬀered saline 0.1% Tween 20
and incubated overnight with p44/42 MAPK (Erk1/2), Phospho-p44/
42 MAPK (Erk1/2) (Thr202/Tyr204), Akt, Phospho-Akt (Ser473)
(1:1000, all from Cell Signaling Technology), ﬁbronectin (1:1000,
ab24139) or beta Actin (1:2000) (both from Abcam) antibodies fol-
lowed by biotinylated secondary antibodies (1:5000, DAKO) and
Vectastain ABC kit (Vector Laboratories). Immunocomplexes were vi-
sualized using a Pierce ECL Western blotting substrate (Thermo
Scientiﬁc) and a Luminescent image analyzer LAS-3000 (Fujiﬁlm).
2.10. Statistical analysis
All assays were repeated 2–4 times. Each myoma experiment was
performed with triplicate myoma discs per culture condition.
Diﬀerences in cell proliferation, Transwell® migration, scratch wound
healing, invasion area, depth and index were evaluated by using
Student's t-test in the IBM SPSS Statistics version 20 software. In all
experiments, a p-value of less than 0.05 was considered signiﬁcant.
3. Results
3.1. MMP9 is expressed in benign and malignant cell lines and its amount
increases during cell migration
We ﬁrst conﬁrmed the expression of MMP9 in various cell lines and
further observed its expression during cell migration. ProMMP9 was
detected in the medium of all oral cell lines of epithelial origin ex-
amined (HGF, IHGK, SCC-25 and HSC-3) (Fig. S1A), but the molecular
weight corresponding to the active form of MMP9 was not detected.
Pro-form of MMP2 was expressed by all of the cell lines and the active
form was also detected in most of the cell lines examined. The ex-
pression of proMMP9 was strongly increased by scratching the HSC-3
cell layer after 24 h (Fig. 1A). The proMMP9 expression in HSC-3 cells
was further increased after 48 h, but at this time point the wounding no
longer induced the expression. Furthermore, no activation of proMMP9
or proMMP2 was detected upon wounding. Similar (but lower) increase
of MMP9 expression was also detected in the migrating breast carci-
noma cell line MDA-MB-231 (Fig. S1B).
3.2. Gelatinase inhibitor peptide CTT2 increases the motility of HSC-3 cells
Because MMP9 expression was increased in migrating cells, we next
examined the eﬀect of MMP9 inhibition on cell migration and invasion.
Gelatinase inhibitor CTT2 – a synthetic cyclic peptide
that speciﬁcally inhibits the activity of gelatinases [13,15] – was
applied to the three diﬀerent OTSCC and MDA-MB-231 cell lines in
Transwell® chambers after attachment (Fig. 1B and S1C-E). As expected
based on previous in vitro ﬁndings on breast cancer cells [28–30], CTT2
inhibited the migration of MDA-MB-231 cells (48 h, p < 0.05, Fig.
S1C). Of the three diﬀerent OTSCC cell lines examined, CTT2 inhibited
the migration of SAS cells (24 h and 48 h, p < 0.05, Fig. S1D), had no
eﬀect on SCC-25 cells (Fig. S1E) and slightly increased the migration of
HSC-3 cells (p= 0.057, Fig. 1B). After 48 h, the diﬀerence in migration
of HSC-3 cells disappeared. In the myoma organotypic culture, the tu-
mour cells treated with CTT2 invaded signiﬁcantly deeper than the
control cells (p < 0.001, Fig. 1C-D). The invasion index was also
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signiﬁcantly higher in CTT2-treated cells than in controls (p < 0.01,
Fig. 1E).
3.3. Silencing of MMP9 increases the migration and invasion of HSC-3 cells
To get further conﬁrmation for the observed inﬂuence of MMP9 on
oral carcinoma cell migration, and because CCT2 also inhibits MMP2
activity, MMP9 was silenced in HSC-3 and SAS cells (which had the
opposite eﬀect on CTT2 inhibition) using lentivirus-mediated RNA in-
terference (shMMP9). The eﬃciency of MMP9 silencing in stable
transduced cell lines was determined by semi-quantitative PCR and
zymography. However, in SAS cells the inhibition of MMP9 was not
successful (not shown), and therefore, we focused our studies only on
HSC-3 cells. In HSC-3 cell culture medium, the protein level of MMP9
was decreased by 30–70% (comparison of band intensities in zymo-
graphy) in silenced cells relative to control cells transduced with
scrambled lentivirus (Fig. 2B). The diminished level of MMP9 mRNA in
cells was also detected by PCR (Fig. 2A). Zymography showed that si-
lencing of MMP9 in HSC-3 cells did not change the level of MMP2 (Fig.
S2A). In addition, MMP9 and MMP2 were only detected in the medium
and not in the cell extracts (Fig. S2A). shMMP9-1 (representing a higher
degree of silencing) and/or -3 (representing a lower degree of silencing)
were used in subsequent experiments. Both shMMP9 clones showed
signiﬁcantly less cell proliferation than control cells (p < 0.001, Fig.
S2B). In line with CTT2 inhibition, shMMP9 cells migrated signiﬁcantly
faster than control cells in the scratch wound assay (p < 0.001,
Fig. 2C, 24 h) and in the Transwell® migration assay (p < 0.001,
Fig. 2D, 24 h and 48 h). Likewise, the invasion area of shMMP9 cells
was slightly increased in myoma organotypic culture (p < 0.05,
Fig. 3A-B). However, in myoma tissue there was no diﬀerence in in-
vasion depth between shMMP9-1 or -3 cells and control cells (Fig. 3C).
Altogether our migration and invasion assays suggested that MMP9
inhibits motility of HSC-3 cells in vitro.
3.4. Fibronectin expression and activation of Akt pathway is upregulated in
shMMP9 HSC-3 cells
To better understand the overall eﬀects of MMP9 silencing on the
cells, we examined the gene expression proﬁles of shMMP9 cells com-
pared with controls in stationary and migrating phenotypes. In silenced
cells, MMP9 expression was conﬁrmed to be downregulated. In sta-
tionary cells, approximately 366 genes reached the FC > 1.5 diﬀerence
in expressions (Supplementary Table 2), whereas in migrating cells the
number of changed genes was 262 (Supplementary Table 3) (GEO)
between the shMMP9 and control cells. The genes were annotated to
functional groups with the DAVID annotation tool [27]. The most sig-
niﬁcant changes between shMMP9 cells and controls were observed in
genes annotating to the GO-terms “Regulation of cell proliferation” and
“Response to wounding” in stationary cells (Supplementary Table 4)
and to “Extracellular region part” and “Response to Wounding” in mi-
grating cells (Supplementary Table 5). Among the upregulated genes in
stationary cells, we found ﬁbronectin, a matrix glycoprotein associated
with various phases of tumorigenesis [31]. The increased amount of
ﬁbronectin was also observed at the protein level (Fig. 4A).
To examine the eﬀect of ﬁbronectin on the migration of shMMP9,
we performed a scratch assay on top of various coatings, including ﬁ-
bronectin. Interestingly, of the three diﬀerent substrates, ﬁbronectin
was the only one that slightly increased the migration of shMMP9 cells
already at 8 h compared with control cells (P= 0.057, Fig. 4B). Type I
collagen and Matrigel did not have a similar eﬀect at this time point
(8 h, Fig. S3). After 24 h, the migration of shMMP9 cells was slightly
increased compared with control cells on all coatings used, but the
increase was signiﬁcant only when non-coated wells were used
(P= 0.029, 24 h, Fig. S3).
Fig. 1. (A) HSC-3 cell cultures were
wounded, and media were collected
with their unwounded controls at 24 h
and 48 h. The level of MMP9 was ana-
lysed from equal amounts of cell cul-
ture media by zymography. Puriﬁed
gelatinase standards are shown on the
left: pro-MMP9 (92 kDa), active MMP9
(82 kDa), pro-MMP2 (72 kDa) and ac-
tive MMP2 (62 kDa). (B) Migration of
HSC-3 cells was analysed with
Transwell® assay in serum-free medium
or in medium containing CTT2. The
cells were ﬁxed and stained with
Toluidine Blue after 24 h or 48 h. The
dye was eluted in SDS and the absor-
bance at 650 nm was measured. N=4
wells per experimental condition. (C)
Invasion of control and 100 μM CTT2-
treated HSC-3 cells was analysed with
myoma organotypic cultures after 10
days. The invasion depth (D) and in-
vasion index (E) of HSC-3 cells were
analysed from pan-cytokeratin stained
myoma sections (three or four myoma
discs per culture condition, each with
16–48 sections) using Fiji software. P-
values were calculated using Student's
T-test. * p < 0.05, ** p < 0.01, ***
p < 0.001.
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Fibronectin aﬀects tumour progress by activating ERK1/2 and Akt/
PI3K pathways [31]. Western blot analysis revealed that MMP9 silen-
cing also increased the phosphorylation of Akt (protein kinase B; PKB),
but it had no eﬀect on total or phosphorylated Erk1/2 (Fig. S4A). Of
note, MMP9 dimers, known to participate in MMP9-induced cell mi-
gration [32], were not detected in any of the cell lines examined (Fig.
S4B).
3.5. MMP9 is involved in mediating the tumour-suppressive eﬀects of
arresten
ArrHSC-3 cells with reduced migration [19] showed increased ex-
pression of MMP9 (but slightly reduced expression of MMP2) (Fig. 5A
and C). To examine whether the increased MMP9 level is of signiﬁcance
in the decreased invasion in this cell line, we inhibited MMP9 by CTT2.
In control cells, CTT2 again slightly increased the cell migration after
24 h (P=0.057, 24 h, Fig. 5B). After 48 h, CTT2 increased the migra-
tion of arrHSC-3 cells to the level of control cells (48 h, Fig. 5B). Also, in
these cells, MMP9 levels were increased due to the migration and after
longer incubation (Fig. 5C). We conﬁrmed the previously shown eﬀect
of arresten on cell motility [19] in various 3D invasion models. We
utilized human myoma tissue discs equilibrated with medium con-
taining arresten to conﬁrm the earlier ﬁndings [19] showing the anti-
migratory eﬀect of arresten. We found cell invasion to be almost
completely prevented by 500 nM arresten (Fig. S5A-D). Arresten
100 nM was not suﬃcient to reduce the invasion. The inhibiting eﬀect
on invasion was also observed in arrHSC-3 cells, where the invasion
depth and the area were signiﬁcantly lower than in control cells in
myoma organotypic culture (p < 0.05 and p < 0.01, respectively, Fig.
S6A–D). Moreover, overexpressed arresten signiﬁcantly increased the
proliferation of HSC-3 cells after 48 h (Fig. S2C, p < 0.001), which was
opposite to what we observed for shMMP9 cells.
4. Discussion
The role of MMP9 in oral carcinoma has been studied extensively in
human cancers, yielding partly contradictory results. Moreover, mouse
experiments have not been able to demonstrate that inhibiting gelati-
nases decreases the invasive spread of oral cancer [14], although in
some cases it decreases [13] or even increases primary tumour growth
[14] depending on the inhibitor(s) used. Despite the highly conﬂicting
and indeﬁnite in vivo evidence on the function of MMP9 in oral cancer,
there are only a few studies evaluating its eﬀects on oral carcinoma
cells in vitro. Hence, in this study, we focused on examining the role of
MMP9 in invasion and migration of oral carcinoma cell lines in vitro
using various technical approaches. Interestingly, we found that al-
though migrating cells increase their MMP9 expression, it may not be
driving, but rather inhibiting, the migration process. We demonstrated
the inhibitory eﬀect of MMP9 on cell motility ﬁrst by using a speciﬁc
inhibitor of MMP2 and -9 activities, the CTT2 peptide, and conﬁrmed
the results by shRNA silencing of MMP9 expression. CTT2 is a synthetic
cyclic peptide, selected from libraries of random peptides shown to
speciﬁcally bind and inhibit the activity of gelatinases (MMP2 and -9)
without aﬀecting their mRNA expression levels [13,15]. Interestingly,
mice with HSC-3 xenograft tumours treated with CTT2 had smaller
primary tumours than the control group [13]. In line with this, we
found that MMP9 inhibits proliferation of HSC-3 cells in vitro. However,
another gelatinase inhibitor CTT1 did not inhibit metastasis formation
[14] in the mouse. Using a combination of gelatinase inhibitors in
mouse OTSCC xenograft model, the tumour size was increased com-
pared with the sole CTT therapy [14]. This clearly demonstrates that
inhibiting gelatinase activities does not have only antitumoral eﬀects in
vivo, as one might expect based on immunohistochemical analyses of
MMP9 expression in human OSCC tissues [4].
We found that CTT2 had diﬀerent eﬀects on the vertical migration
Fig. 2. MMP9 silencing in HSC-3 cells
stable transduced with three diﬀerent
MMP9 lentiviral shRNAmir particles
(shMMP9-1, -2 and 3) was veriﬁed by
(A) PCR and (B) zymography. β-actin
(ACTB) was used to control the RNA
amount. The values represent the
quantitation of the band intensities
compared with control. Zymography
was performed using equal amounts of
culture media. Scrambled shRNAmir
particles transduced HSC-3 cells were
used as a control (control HSC-3 cells)
in experiments. Puriﬁed gelatinase
standards are shown on the right: pro-
MMP9 (92 kDa) and active MMP9
(82 kDa). For further experiments,
shMMP9 cell lines -1 and -3 were used.
(C) Migration of the control and
shMMP9 HSC-3 cells was analysed with
a scratch wound assay. The wounds
were photographed with EVOS photo
microscope after 24 h and the area of
open wound was measured as de-
scribed in methods. White stripes in the
wound photographs represent the
edges of the wound at time point 0 h.
Results are the mean of 4 samples. (D)
Migration of shMMP9 cells (shMMP9-1
and -3) was analysed with Transwell®
assay in serum-free medium. The cells
on the underside of membranes were
stained with crystal violet after 24 h or
48 h, photographed and the area of migrated cells was measured using QWin V3 software. Results represent the mean of 6 samples. P-values were calculated using
Student's T-test. * p < 0.05, ** p < 0.01, *** p < 0.001.
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of various OTSCC cell lines: it had no eﬀect on SCC-25, inhibited SAS,
but increased the migration of the most aggressive and highly meta-
static HSC-3 cell line [33,34]. Thus, our data suggest that mechanisms
of MMP9 depend on the various genetic and cellular properties of
OTSCC cells. In earlier studies, CTT2 was shown to inhibit the migra-
tion of HSC-3 cells [13,35]. However, in those experiments, CTT2 was
applied to the cells prior to their plating, unlike in our experiments,
where the inhibitor was added after the cells were attached to the wells.
These experimental diﬀerences most likely caused the discrepancies in
cell migration results since we were able to conﬁrm the inhibitory eﬀect
of CTT2 on HSC-3 48 h migration by allowing the cells to attach in the
presence of CTT2 (data not shown), as previously described. Likewise,
CTT2 increased the invasion of HSC-3 cells in human myoma organo-
typic culture, in which the eﬀect of CTT2 on migration was more drastic
than in the Transwell migration assay. This might be due to anti-pro-
liferative eﬀects of MMP9 inhibition that most likely aﬀects less in the
myoma model. In myoma, cells keep their migratory (rather than pro-
liferative) phenotype longer that in Transwells, where they reach the
membrane and might thereafter adapt the proliferative phenotype.
HSC-3 cells expressed more MMP9 than MMP2, so the inducing eﬀect of
CTT2 on the invasion of HSC-3 cells is likely due to MMP9 inhibition.
This was conﬁrmed by shRNA silencing of MMP9, which signiﬁcantly
induced the migration of HSC-3 cells, as we showed by various ex-
perimental models. The decreased proliferation of MMP9-silenced HSC-
3 cells (shMMP9) could also be a result of an increased migratory
phenotype. The ﬁnding that MMP9 silencing can in certain conditions
decrease the cell proliferation may also explain the previous results that
CTT2 inhibits tumour growth in a mouse model [13].
We have previously shown that HSC-3 cells invading myoma to-
gether with M1 macrophages have a higher level of MMP9 than in the
presence of M2 macrophages [36]. Importantly, M2 macrophage is the
phenotype displayed by most tumour-associated macrophages able to
induce cancer growth [36]. We have also demonstrated that MMP8-
overexpressing HSC-3 cells, with signiﬁcantly decreased cell invasion
and migration, have increased MMP9 expression [12]. Here, we further
showed that arrHSC-3 cells, also revealed to have reduced motility
[19], had elevated MMP9 expression levels and a concomitant reduc-
tion in the amount of MMP2. In these cells, inhibiting MMP9 activity by
gelatinase inhibitor CTT2 (which inhibits both MMP9 and MMP2) re-
stored their migration. This demonstrates that the decreased migration
capacity of arresten-overexpressing cells was partly due to increased
MMP9 expression. These ﬁndings further suggest the important in-
hibitory role of MMP9 in cell invasion and migration of an aggressive
HSC-3 cell line.
Fibronectin, one of the upregulated genes in shMMP9 HSC-3 cells, is
connected to the pathogenesis of OTSCC [37,38], and it regulates and
activates MMP9 in breast and laryngeal cancers [39,40]. Fibronectin
aﬀects tumour progression by altering MMP expression and activating
Fig. 3. (A) Invasion of control and shMMP9 HSC-3 cells was analysed using myoma organotypic cultures and the invasion area and depth were measured from pan-
cytokeratin stained sections (B-C). In myoma experiments, 3× 105 shMMP9 or control HSC-3 cells were cultured for 10 days on top of the myoma discs. Myoma
experiments were performed once with three or four myoma discs per culture condition, 16–48 pan-cytokeratin stained sections per condition were analysed using
Fiji software. P-values were calculated using Student's T-test. * p < 0.05, ** p < 0.01, *** p < 0.001.
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ERK1/2 and Akt/PI3K pathways via FAK phosphorylation and Src re-
cruitment [31]. It promotes in vitro invasion and migration of A549
lung cancer cells [31] and activates the PI3K/Akt pathway in hepato-
cellular carcinoma [41]. Fibronectin itself is induced through the PI3K/
Akt pathway in human retinal pigmental epithelial cells [42]. Con-
comitantly, phosphorylation of Akt was increased in our MMP9-si-
lenced HSC-3 cells. The Akt pathway regulates the expression of a range
of proteins involved in the modulation of cell proliferation and growth
[43] and is one of the downstream eﬀectors of the EGFR signalling
pathway. The activation of PI3K/Akt signalling, a tumour-promoting
pathway, may reﬂect or be a result of the increased aggressiveness of
shMMP9 cells. Activation of PI3K/Akt signalling has been linked to
shorter disease-free survival and worse outcome also in OTSCC [44,45].
The ﬁnding that shMMP9 cells migrated slightly faster on ﬁbronectin
coating than control cells might be a result of their improved response
to extracellular ﬁbronectin due to their increased exogenous ﬁbronectin
expression. Interestingly, MMP9 dimers, which have been shown to be
essential for MMP9-enhanced cell migration in MD-MBA-435 breast
cancer cells [32], were not detected in any of the cell lines here. The
activation of MMP9 is also aﬀected by the capability of proMMP9 to
form dimers, such as hetero- or homodimers, through its C-terminal
hemopexin (HPX) domain [46]. It is possible, though, that in our ex-
perimental settings homodimers are formed very locally, and thus, are
not detected by zymography.
MMP9 is a diﬃcult target for anticancer drug development, mainly
because of its both pro- and anti-tumorigenic eﬀects [47]. A meta-
analysis found that MMP9 overexpression is a predictor of poor prog-
nosis in OTSCC patients [4]. However, its eﬀect on tumour progression
in OTSCC is unclear. Although there are publications showing a pro-
tumorigenic role for MMP9 in cancer progression [48,49], most studies
support our ﬁndings. Stokes et al. showed that MMP9 mRNA in primary
tumours was signiﬁcantly decreased in those head and neck squamous
cell carcinomas with metastasis compared with non-metastatic tumours
[8]. Moreover, there is evidence from other cancer types supporting the
protective role of MMP9. Vaccinia virus-mediated gene transfer of
MMP9 regressed prostate cancer growth [50], and MMP9 gene transfer
by adenovirus dose-dependently decreased tumour growth in breast
cancer [51]. MMP9 has previously been reported to have anti-tumori-
genic eﬀects also on skin and colon cancer via its involvement in in-
vasion and angiogenesis [52]. In addition, MMP9 deﬁciency resulted in
skin tumours with higher malignant grades in K14-HPV16 transgenic
mice [53]. There are also studies based on patient data where a cor-
relation between MMP9 expression and poor prognosis in OTSCC has
not been found [54] and where MMP9 expression showed a tendency
(i.e. not signiﬁcant) for better prognosis [55]. Because of the dis-
crepancy between in vivo and in vitro ﬁndings, results gained solely with
tumour cells, such as ours here, should be viewed critically. The com-
plexity of TME is, after all, beyond any in vitro models, as they lack the
elements that angiogenesis aﬀects (vascularity) as well as inﬂammatory
cells and other possible proteins or co-factors that may be involved in
the pathways of enzyme activity. However, we wanted to mimic the
TME in our in vitro experiments, and hence, also used our human
myoma-derived organotypic model to more reliably evaluate the eﬀects
of MMP9 on cell behaviour [22,23]. Because of the diversity of the
eﬀects and functions of MMP9 reported in vitro, it would be highly
important to evaluate whether the upregulated MMP9 in vivo has a true
pathogenic eﬀect or whether the upregulation is actually caused by the
disease. The upregulation of MMP9 may also be a protective response of
the host against the tumour [47], as in the case of MMP8 [12,55].
MMPs in vivo may play both pro- and antitumorigenic roles, depending
on the nature of the cancer.
5. Conclusions
Our study provides strong evidence for the inhibiting eﬀects of
MMP9 on motility of HSC-3 cells, an oral tongue carcinoma cell line
with a high metastatic potential. However, based on our experiments
with CTT2 inhibitor, other OTSCC cell lines responded diﬀerently to the
changes in MMP9 levels, suggesting that mechanisms of MMP9 depend
on the various genetic and cellular properties of the cell lines. Although
high MMP9 expression is usually linked to poor prognosis of OTSCC
patients, our study suggests that it might not solely drive tumour pro-
gression, but may also have anti-migratory, yet unidentiﬁed, eﬀects on
OTSCC. More in vivo studies are needed to reveal the function of MMP9
in diﬀerent stages of OTSCC progression.
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